Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus Target Price from Brokerages

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNCGet Free Report) have been assigned a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.39.

Several equities research analysts recently commented on RVNC shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho dropped their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. HC Wainwright reissued a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. StockNews.com initiated coverage on Revance Therapeutics in a research report on Tuesday, January 21st. They issued a “hold” rating for the company. Finally, Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd.

View Our Latest Stock Report on Revance Therapeutics

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RVNC. Deltec Asset Management LLC bought a new position in shares of Revance Therapeutics in the 4th quarter worth approximately $304,000. Inspire Investing LLC boosted its stake in Revance Therapeutics by 69.0% during the 4th quarter. Inspire Investing LLC now owns 131,892 shares of the biopharmaceutical company’s stock valued at $401,000 after purchasing an additional 53,837 shares during the last quarter. FNY Investment Advisers LLC boosted its stake in Revance Therapeutics by 160.4% during the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 294,323 shares during the last quarter. Exome Asset Management LLC purchased a new stake in Revance Therapeutics during the 3rd quarter valued at $1,804,000. Finally, Oddo BHF Asset Management Sas purchased a new stake in Revance Therapeutics during the 3rd quarter valued at $3,763,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Up 0.3 %

Shares of RVNC opened at $3.65 on Friday. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.86. The business has a 50-day simple moving average of $3.41 and a two-hundred day simple moving average of $4.60. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.56.

Revance Therapeutics (NASDAQ:RVNCGet Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. On average, equities research analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.

Revance Therapeutics Company Profile

(Get Free Report

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Further Reading

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.